How Replimune’s drug got a third chance after the White House intervened
RSS SUMMARY · AGGREGATED FROM TWSJ
Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.
Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.
Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
Ships Are Sailing ‘Dark’ to Sneak Out of Strait of Hormuz
TWSJ·1h ago·3 min read
Tech
The Google Engineer Accused of Risking It All With an Insider Polymarket Bet
TWSJ·3h ago·3 min read
World News
The U.N. Is Going Broke as the U.S. and China Withhold Billions
TWSJ·2h ago·3 min read
Tech
Robotaxis Are Spreading Across the U.S.—and So Is the Backlash
TWSJ·3h ago·3 min read
Related
On this beat
Health
Passengers from a hantavirus ship might soon be allowed to leave Nebraska facility. The White House is asking states to monitor them 24/7.
TWSJ·6h ago·3 min read
Health
Creating A More Comfortable And Relaxing Living Environment
AOHL·11h ago·3 min read
Health
Best Eco-Friendly Athletic Flooring Options That Actually Perform
AOHL·11h ago·3 min read
Health
Wealthy retirees are buying ‘med-à-terres,’ this enigmatic therapy worked for one writer and cholesterol-lowering drugs are on the horizon. Read more in this week’s WSJ Health newsletter:
TWSJ·11h ago·3 min read